Home

Christy J. Oliger

CIK 1822092 · last filed 2026-09-02

Christy J. Oliger is a corporate insider who has filed 31 SEC Form 4 insider transactions across 10 companies since 2020. The most recent filing, for ZBIO, was dated Sep 2, 2026. Current disclosed insider exposure totals $27.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$27.1K

Companies

10

Total Filings

31

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
85 WELLS AVENUE
SUITE 210
NEWTON, MA 02459
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ZBIO Director — $29.63 — $0 1 2026-09-02
BCAX Director — $20.48 — $0 1 2026-07-29
Nuvalent, Inc. (NUVL) Delisted Director 0 $123.96 $0 $0 3 2026-07-15
VERA Director — $33.05 — $0 3 2026-05-26
KPTI Director 15,508 $1.75 $27.1K $0 7 2026-05-26
REPL Director — $12.96 — $0 6 2026-04-07
LAVA Therapeutics NV (LVTX) Delisted Director — $1.74 — $0 2 2025-11-17
RayzeBio, Inc. (RYZB) Delisted Director — $62.49 — $0 1 2024-02-27
REATA PHARMACEUTICALS INC (RETA) Delisted Director 0 $172.36 $0 $0 5 2023-09-26
Sierra Oncology, Inc. (SRRA) Delisted Director — $54.99 — $0 2 2022-07-01

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 ZBIO Grant (A) — $0 EDGAR
2026-07-29 BCAX Grant (A) — $0 EDGAR
2026-07-15 Nuvalent, Inc. (NUVL) Delisted Mixed −7,415 -$164.2K EDGAR
2026-06-18 Nuvalent, Inc. (NUVL) Delisted Grant (A) +3,444 $0 EDGAR
2026-05-26 VERA Grant (A) — $0 EDGAR
2026-05-26 KPTI Grant (A) +15,508 $0 EDGAR
2026-04-07 REPL Grant (A) — $0 EDGAR
2025-11-17 LAVA Therapeutics NV (LVTX) Delisted Disp (D) — $0 EDGAR
2025-06-20 Nuvalent, Inc. (NUVL) Delisted Grant (A) +3,971 $0 EDGAR
2025-05-29 KPTI Grant (A) — $0 EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.